chronic kidney disease

Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating…

Sun Pharma to market the drug under the brand name Lyvelsa

The drug will be marketed by Sun Pharma under the brand name RYTSTAT. Zydus continues to market the drug under the brand name…

Unlike CKD, which arises from old age, diabetes, cardiovascular disease, and other medical problems, patients with CKDu do not…

Forxiga is the first-ever approved medicine for the treatment of the disease in Japan

It is a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR…

They are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis

JBCPL to launch seven products in the division that will focus on the management of hypertension in Chronic Kidney Disease to…

In DAPA-CKD Phase III trial, FARXIGA demonstrated reduction in the risk of the composite of worsening of renal function, end-stage…

They are indicated for the control of serum phosphorus in adults and children six years of age and older with chronic kidney…